Today: 17 June 2026
Browse Category

NASDAQ:ARCT 22 October 2025

Arcturus Therapeutics Stock Soars to New High Then Crashes on Trial Data – What Investors Need to Know

Arcturus Therapeutics Stock Soars to New High Then Crashes on Trial Data – What Investors Need to Know

Arcturus stock hit a 52-week high of $24.17 on Oct. 21 before plunging up to 60% after mixed Phase 2 cystic fibrosis trial results. Interim data showed ARCT-032 was generally safe and reduced lung mucus in most patients, but failed to improve primary lung-function measures. A higher-dose cohort is underway. Analyst ratings remain moderately positive, with price targets averaging $50.
22 October 2025

Stock Market Today

  • Stocks Indexes Slip as Chipmakers and Energy Sector Weigh; Dow Hits Record High
    June 17, 2026, 5:11 AM EDT. Stock indexes closed mixed Tuesday with the S&P 500 down 0.57%, Nasdaq 100 off 1.89%, and Dow Jones Industrial Average rising 0.64% to a new all-time high. Chipmakers declined, dragging tech-heavy Nasdaq lower. Energy shares tumbled on a 5% drop in crude oil prices after the US-Iran deal to reopen the Strait of Hormuz, easing supply concerns. U.S. May housing starts fell sharply, hitting a six-year low and raising concerns over the real estate sector. The 10-year Treasury yield fell 5 basis points to 4.42%. Markets now eye the Federal Reserve's two-day meeting under new Chair Kevin Warsh, expecting no rate changes but watchful for forward guidance. Overseas indexes traded mixed, with the Euro Stoxx 50 up 0.45%, China's Shanghai Composite down 0.11%, and Japan's Nikkei reaching a record high.

Latest articles

Our Bond shares edge lower after sharp rally on debt swap, city license updates

Our Bond shares edge lower after sharp rally on debt swap, city license updates

17 June 2026
Our Bond Inc. shares fell 8.1% to $1.02 premarket after a 108.5% surge, as investors digested a $3.3 million debt-for-preferred-equity swap at a $2.0265 conversion price—over 200% above recent levels—and a municipality-funded license deal covering 270,000 residents, with CEO Doron Kempel set to address investors at 11:00 a.m. ET.
AST SpaceMobile Drops Premarket After SpaceX BlueBird 8-10 Launch

AST SpaceMobile Drops Premarket After SpaceX BlueBird 8-10 Launch

17 June 2026
AST SpaceMobile shares dropped about 6% to $82.25 in early premarket trading after SpaceX confirmed deployment of three new BlueBird satellites, a key test following April’s costly BlueBird 7 loss; investors face near-term risks around satellite commissioning, regulatory approvals, and execution despite reaffirmed 2026 satellite targets and $150–200 million revenue guidance.
Go toTop